Description du projet
L’administration ciblée de médicaments grâce à la nanotechnologie
Les médicaments chimiothérapeutiques se caractérisent par des effets hors cible dans les tissus sains et souvent une biodistribution plus faible dans la tumeur. Le projet SMARTRIOX, financé par l’UE, a développé un système à base de nanoparticules qui peut être programmé pour délivrer le médicament requis à sa cible. Cette spécificité repose sur des molécules d’ADN qui répondent à certains stimuli dans les tissus cibles et libèrent le médicament. Les chercheurs utiliseront ce système pour le traitement du cancer du sein triple négatif, un type de cancer du sein agressif et difficile à traiter. Le principal avantage du système est qu’il peut être adapté en fonction des besoins des patients à l’hôpital, offrant un moyen d’administration de médicaments facilement accessible.
Objectif
Although there are Triple Negative Breast Cancer (TNBC), the most aggressive type of Breast Cancer (BC), accounts for 15-25% of all BCs. Yearly 200,000 women are diagnosed with TNBC, of which 100,000 are diagnosed with metastatic disease at the primary diagnosis. TNBC lacks a recognized molecular target, making it an orphan disease: no effective treatment is available to date. The poor prognosis of patients suffering from TNBC makes it extremely challenging for both oncologists and patients. TNBC is more aggressive because all its receptors (Estrogen/Progesterone/Herceptin) are negative, and targeted and endocrine therapies are not helpful. TNBC shows a shortened disease-free interval in the neoadjuvant and adjuvant settings and a more aggressive course in the metastatic setting.The mainstay treatment for TNBC is Doxorubicin, a potent anthracycline chemotherapy, which nonetheless, has substantial toxicities (cardiac, immune, digestive and epithelial) that limit its maximal dose and render the tumour cells resistant to it. As a result, patients cannot be treated with a high enough and effective dose.In response, Triox Nano has developed TXN770: an innovative bionanoparticle based anticancer treatment. TXN770 has a DNAzyme machine cap that recognizes cancer cells and releases the chemotherapy exclusively inside them, responding to pre-programmed threshold levels of Mg2+ and ATP that are present primarily at the target TNBC cells. This allows using 4 times lower concentrations of Doxorubicin, which in turn causes less side effects and achieves a higher effectiveness. It also prevents cancer cells from becoming resistant to Doxorubicin.TrioxNano will address a BC world market of $10.4 billion, expected to grow to $17.2 billion in 2021. TrioxNano projects €547M in profit, with a ROI of €15 per euro invested in the project and in turn will help ease the economic burden of TNBC in National Health Services while positioning itself as a leading company in treatment of TNBC.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesbiological sciencesgeneticsDNA
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural scienceschemical sciencespolymer sciences
- medical and health sciencesclinical medicineoncologybreast cancer
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- engineering and technologynanotechnologynano-materials
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
9518705 Jerusalem
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.